Your browser doesn't support javascript.
loading
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom.
Sundar, Sudha; Manchanda, Ranjit; Gourley, Charlie; George, Angela; Wallace, Andrew; Balega, Janos; Williams, Sarah; Wallis, Yvonne; Edmondson, Richard; Nicum, Shibani; Frost, Jonathan; Attygalle, Ayoma; Fotopoulou, Christina; Bowen, Rebecca; Bell, Dani; Gajjar, Ketankumar; Ramsay, Bruce; Wood, Nicholas J; Ghaem-Maghami, Sadaf; Miles, Tracie; Ganesan, Raji.
Affiliation
  • Sundar S; Gynaecological Oncology, Pan-Birmingham Gynaecological Cancer Centre, Birmingham, UK sudha.sundar@nhs.net.
  • Manchanda R; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Gourley C; Gynaecological Oncology, Barts Health NHS Trust, Barts Cancer Institute, London, UK.
  • George A; University of Edinburgh Cancer Research UK Centre, Edinburgh, UK.
  • Wallace A; Royal Marsden Hospital NHS Trust, London, UK.
  • Balega J; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.
  • Williams S; Gynaecological Oncology, Pan-Birmingham Gynaecological Cancer Centre, Birmingham, UK.
  • Wallis Y; University Hospital Birmingham Foundation NHS Trust, Birmingham, UK.
  • Edmondson R; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
  • Nicum S; University of Manchester, Manchester, UK.
  • Frost J; Oxford University Hospitals NHS Trust, Oxford, UK.
  • Attygalle A; Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
  • Fotopoulou C; Pathology, Royal Marsden NHS Foundation Trust, London, UK.
  • Bowen R; Gynaecologic Oncology, Imperial Hospitals NHS trust, London, UK.
  • Bell D; Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
  • Gajjar K; Macmillan Cancer Support, London, UK.
  • Ramsay B; Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Wood NJ; Peterborough City Hospital, Peterborough, Cambridgeshire, UK.
  • Ghaem-Maghami S; Obstetrics and Gynaecology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
  • Miles T; Imperial College London, London, UK.
  • Ganesan R; Gynaecological Oncology, Royal United Hospitals, Bath, UK.
Int J Gynecol Cancer ; 31(2): 272-278, 2021 02.
Article in En | MEDLINE | ID: mdl-33468564
ABSTRACT
The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / BRCA1 Protein / BRCA2 Protein / Carcinoma, Ovarian Epithelial Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Country/Region as subject: Europa Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / BRCA1 Protein / BRCA2 Protein / Carcinoma, Ovarian Epithelial Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Country/Region as subject: Europa Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2021 Document type: Article Affiliation country:
...